Selpercatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Selpercatinib: From RET-Altered Cancer to Pulmonary Hypertension
One-Sentence Summary
Selpercatinib is a highly selective RET kinase inhibitor whose established use, per the cited literature, is in RET fusion-positive non-small-cell lung cancer (formal EU regulatory indication text is not available in this evidence pack). The TxGNN model’s top prediction is Pulmonary Hypertension (score 99.18%), but this candidate is currently supported only by an AI knowledge-graph score — the two associated publications discuss selpercatinib’s real-world oncology safety profile, not pulmonary hypertension, and are flagged in the evidence pack itself as likely graph noise.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | RET fusion-positive NSCLC (inferred from literature; no formal EU indication text on file — drug not yet authorized) |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, Selpercatinib is described as a highly selective RET kinase inhibitor, and its use in RET fusion-positive/mutated cancers (NSCLC and related RET-driven tumours) is supported by the real-world literature cited here.
There is no established mechanistic link between RET kinase signaling and pulmonary vascular remodeling — the pathophysiology of pulmonary hypertension is more commonly associated with BMPR2/TGF-β signaling. The evidence pack’s own rationale explicitly characterizes this prediction as likely knowledge-graph co-occurrence noise rather than a genuine drug–disease relationship: the two cited papers concern selpercatinib’s adverse-event profile in oncology patients (PMID 39372206) and its real-world efficacy in RET fusion-positive NSCLC (PMID 34178121) — neither addresses pulmonary hypertension as a treatment target. The same pattern (score-driven ranking with no supporting mechanism or clinical data) is seen across all ten TxGNN-ranked candidates in this pack, several of which are rare/obsolete disease entries with no plausible RET connection.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39372206 | 2024 | Real-world safety cohort | Frontiers in Pharmacology | Compared adverse event profiles of pralsetinib vs. selpercatinib using FDA FAERS data; addresses oncology-setting safety, not pulmonary hypertension. |
| 34178121 | 2021 | Retrospective cohort (SIREN) | Therapeutic Advances in Medical Oncology | Real-world efficacy/safety of selpercatinib in RET fusion-positive NSCLC treated through an access program; does not evaluate pulmonary hypertension. |
Neither publication provides direct or indirect support for a pulmonary hypertension indication; both concern selpercatinib’s established oncology use.
Cytotoxicity
Selpercatinib is a targeted oncology agent (RET fusion-positive NSCLC per literature), so this section is included.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (selective RET kinase inhibitor) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten TxGNN-ranked candidates for selpercatinib, including the top-ranked pulmonary hypertension prediction, are Evidence Level L5 — model-score-only with no supporting clinical trials, and the associated literature is explicitly identified in the evidence pack as knowledge-graph noise rather than genuine mechanistic or clinical support. Two blocking/high-severity data gaps (missing TFDA/EU safety labeling and missing MOA data) also prevent even a preliminary safety review (S1).
To proceed, the following is needed:
- Confirmed mechanism of action data from DrugBank (DG002)
- Official safety labeling (warnings, contraindications, DDI) from a regulatory source (DG001)
- Independent mechanistic or preclinical evidence linking RET signaling to pulmonary vascular remodeling before any further investment in this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.